Finoriq research workspace
Atara Biotherapeutics, Inc. (ATRA) SEC Filings & Filing Highlights
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients. Review ATRA SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
- Company
- Atara Biotherapeutics, Inc. (ATRA)
- Ticker
- ATRA
- Market Cap
- $75.6M
- Latest Price
- $8.39
- Industry
- Biotech & Pharma
Atara Biotherapeutics, Inc. (ATRA) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Atara Biotherapeutics, Inc. (ATRA).
| Event | Form | Date |
|---|---|---|
| Departure, Election or Appointment of Directors or OfficersDeparture, Election or Appointment of Directors or Officers | 8-K5.02 | 2026-06-26 |
| On June 9, 2026, the Company held its 2026 annual meeting of stockholders. The following is a b...On June 9, 2026, the Company held its 2026 annual meeting of stockholders (the “Annual Meeting”). The following is a brief description of e... | 8-K5.07 | 2026-06-12 |
| On June 11, 2026, the Board of Directors (the “Board”) of Atara Biotherapeutics, Inc. (the “Com...On June 11, 2026, the Board of Directors (the “Board”) of Atara Biotherapeutics, Inc. (the “Company”) appointed Brian Cherry to serve as a... | 8-K5.02 | 2026-06-12 |
| Press Release, dated May 12, 2026Cover Page Interactive Data File (embedded within the Inline XBRL document) | 8-K9.01 | 2026-05-12 |
| Atara Biotherapeutics Provides Regulatory Update on TabelecleucelAtara Biotherapeutics Provides Regulatory Update on Tabelecleucel | 8-K8.01 | 2026-05-07 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.